| T2DM (n = 50) | Control (n = 32) | p value |
---|---|---|---|
Age (year) | 55 ± 7 | 54 ± 6 | 0.483 |
Male (n, %) | 28 (56) | 17 (53.1) | 0.799 |
BMI (kg/m2) | 24.7 ± 3.7 | 23.7 ± 2.3 | 0.165 |
Diabetes duration (year) | 10 (6–13) | – | – |
HR (bpm) | 69 ± 9 | 66 ± 9 | 0.128 |
SBP (mmHg) | 128 ± 14 | 124 ± 10 | 0.215 |
DBP (mmHg) | 78 ± 10 | 75 ± 8 | 0.159 |
Hypertension (n, %) | 19 (38) | – | – |
Diabetic complication (n, %) | |||
 Retinopathy | 14 (28) | – | – |
 Neuropathy | 10 (20) | – | – |
 Peripheral vascular disease | 6 (12) | – | – |
 Hematocrit (%) | 39.3 ± 4.1 | 41.7 ± 3.7 | 0.009* |
 BUN (mmol/L) | 5.3 ± 1.6 | – | – |
 Creatinine (μmol/L) | 68.9 ± 14.7 | – | – |
 Total cholesterol (mmol/L) | 4.4 ± 1.0 | – | – |
 Triglycerides (mmol/L) | 1.62 ± 1.2 | – | – |
 HDL-C (mmol/L) | 1.3 ± 0.3 | – | – |
 LDL-C (mmol/L) | 2.5 ± 0.7 | – | – |
 FPG (mmol/L) | 8.3 ± 3.3 | – | – |
 Hemoglobin A1C (%) | 8.9 ± 2.3 | – | – |
Hypoglycemic medication, n (%) | |||
 Insulin | 24 (48) | – | – |
 Metformin | 22 (44) | – | – |
 Sulfonylurea | 10 (20) | – | – |
Other medication, n (%) | |||
 Statin | 21 (42) | – | – |
 Aspirin | 16 (32) | – | – |
 ACEI | 20 (40) | – | – |
 Diuretics | 5 (10) | – | – |
 Calcium channel blockers | 5 (10) | – | – |
 β-blockers | 9 (18) | – | – |